DNA Today: A Genetics Podcast

← DNA Today: A Genetics Podcast16 okt · 30 min

#416 How Baby KJ Became the First Patient Treated With Personalized CRISPR

#416 How Baby KJ Became the First Patient Treated With Personalized CRISPR16 okt30 min

CRISPR has carried enormous promise since scientists first realized its potential to edit the human genome, but it has also raised some of the biggest ethical questions in modern genetics.

In this episode, Kira Dineen sits down with Dr. Kiran Musunuru to trace the evolution of human gene editing, beginning with the controversial 2018 announcement that scientist He Jiankui had used CRISPR to edit human embryos in China, resulting in the birth of the world’s first gene-edited babies. The experiment, which targeted the CCR5 gene in an attempt to reduce susceptibility to HIV, sparked international condemnation and intensified debate over germline genome editing, where genetic changes could potentially be passed on to future generations.

From there, the conversation shifts to a dramatically different application of CRISPR: treating serious genetic disease in an individual patient.

Dr. Musunuru shares the remarkable story of Baby KJ, who was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency and became the first patient to receive a personalized CRISPR-based therapy designed specifically for his genetic variant. The team developed KJ’s customized base-editing treatment in approximately six months, moving from identification of his variant through preclinical testing, manufacturing, regulatory review, and ultimately treatment.

Dr. Musunuru explains how KJ’s therapy works, what researchers have learned from his response so far, and whether his case could establish a new pathway for treating patients with ultra-rare genetic conditions who may never fit into a traditional drug-development model.

This interview was recorded in person at AGBT Precision Health in Coronado, California, we caught up with Dr. Musunuru after a presentation.

Episode Discussion Topics:

The 2018 announcement of the world’s first CRISPR-edited babies in China

Why He Jiankui’s experiment targeting the CCR5 gene sparked global scientific and ethical backlash

The difference between editing embryos and germline cells versus editing somatic cells in a patient

What the CRISPR babies controversy taught the scientific community about oversight, regulation, and responsible use of gene-editing technology

How the field of CRISPR medicine has evolved since 2018